GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed price. Currency in AUD
0.016
-0.001 (-5.882%)
As of 10:56AM AEDT. Market open.
Stock chart is not supported by your current browser
Previous close0.017
Open0.016
Bid0.000 x 10000000
Ask0.000 x 64980000
Day's range0.016 - 0.016
52-week range0.006 - 0.021
Volume3,171,428
Avg. volume13,947,776
Market cap38.964M
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-0.004
Earnings date1 Mar. 2016 - 5 Mar. 2016
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • GlobeNewswire5 days ago

    Genetic Technologies Announces Strategic Alliance and Capital Raising

    MELBOURNE, Australia, Feb. 15, 2018-- Genetic Technologies Limited a molecular diagnostics company and provider of BREVAGen plus ®, a first-in-class, clinically validated risk assessment test for sporadic ...

  • GlobeNewswire8 days ago

    Genetic Technologies Limited: Update on Strategic Alliance

    MELBOURNE, Australia, Feb. 12, 2018-- Genetic Technologies Limited, wishes to advise that the Company is presently in discussions with the ASX regarding the possible application of ASX Listing Rule 11.1; ...

  • GlobeNewswire14 days ago

    Change of Chief Executive Officer

    MELBOURNE, Australia, Feb. 06, 2018-- Genetic Technologies Limited, advises that the Board and Mr Eutillio Buccilli have today agreed that Mr Buccilli step down as Chief Executive Officer with immediate ...

  • GlobeNewswire15 days ago

    Appointment of Chairman

    MELBOURNE, Australia, Feb. 05, 2018-- Genetic Technologies Limited, is pleased to announce that the Board of Directors has appointed Dr Paul A. Kasian as Chairman. This follows previous Chairman Dr Malcolm. ...

  • GlobeNewswire20 days ago

    Results from 31 January 2018 General Meeting

    MELBOURNE, Australia, Jan. 31, 2018--. Genetic Technologies Limited advises that a General Meeting of shareholders that had been requisitioned pursuant to section 249 D of the Corporations Act was held ...

  • GlobeNewswire21 days ago

    Resignation of Directors

    MELBOURNE, Australia, Jan. 30, 2018-- Genetic Technologies Limited, advises that Dr Malcolm R. Brandon and Mr Grahame Leonard, AM have resigned as directors of the Company with effect from 29 January, ...

  • GlobeNewswire22 days ago

    Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2017

    Completed a three month promotional campaign leading up to and throughout October Breast Cancer Awareness Month Ohio State University: patient recruitment for the collaborative clinical research study ...

  • GlobeNewswirelast month

    Genetic Technologies Regains Nasdaq Listing Compliance

    MELBOURNE, Australia, Jan. 09, 2018-- Genetic Technologies Limited, is pleased to advise that the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ...

  • GlobeNewswire2 months ago

    Genetic Technologies Provides Update on Strategic Review Initiative

    MELBOURNE, Australia, Dec. 12, 2017-- Genetic Technologies Limited, a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGen plus ®, a first-in-class, clinically validated ...

  • GlobeNewswire3 months ago

    Notice Received Under Section 249D of the Corporations Act

    MELBOURNE, Australia, Dec. 01, 2017-- Genetic Technologies Limited, advises that on 29 November it received a notice under Section 249 D of the Corporations Act 2001 requesting the Company call and arrange ...